DISCOUNT ZERTIFIKAT - ASTRAZENECA | Real-time Boerse Frankfurt Warrants 06:51:00 04/06/2024 pm IST | ||
| 132.7 EUR | +0.21% |
|
| Current month | +1.16% | ||
| 1 month | +2.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 04/24/04 | 132.7 | +0.21% |
| 03/24/03 | 132.4 | +1.16% |
| 31/24/31 | 130.9 | +0.47% |
| 30/24/30 | 130.3 | +0.68% |
| 29/24/29 | 129.4 | -0.48% |
Real-time Boerse Frankfurt Warrants
Last update June 04, 2024 at 06:51 pm IST
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| WKN | PC3VZE |
| ISIN | DE000PC3VZE7 |
| Date issued | 25/01/2024 |
| Maturity | 20/06/2025 (381 Days) |
| Parity | 1 : 1 |
| Emission price | 114.7 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 132.7 € |
|---|---|
| Lowest since issue | 106.3 € |
| Spread | 0.05 € |
| Spread % | 0.04% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.9
USD
Average target price
172.1
USD
Spread / Average Target
+8.96%
- Stock Market
- Certificates
- Certificat
